Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphatic Diseases × dacetuzumab × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Lymphoproliferative Disorders 1 Lymphatic Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hematologic Diseases 1

Interventions

venetoclax 1 ponatinib 1 ibrutinib 1 fludarabine 1 enzalutamide 1 dacetuzumab 1 blinatumomab 1 Rituximab 1 Cyclophosphamide 1 CA-4948 1 ARQ531 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡